Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

  title={Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.},
  author={Ryan Vandrey and Jeffrey C. Raber and Mark E Raber and Brad Douglass and Cameron Miller and Marcel O Bonn-Miller},
  volume={313 24},
Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16% to 26% of patients using medical cannabis consume edible products.1,2 Even though oral consumption lacks the harmful by-products of smoking, difficult dose titration can result in overdosing or underdosing, highlighting the importance of accurate product labeling… 

Tables from this paper

Labeling Accuracy of Cannabidiol Extracts Sold Online

To maximize sampling and ensure representativeness of available products, this work examined the label accuracy of CBD products sold online, including identification of present but unlabeled cannabinoids.

Tasty THC: Promises and Challenges of Cannabis Edibles.

The current state of research regarding edibles is explored, highlighting the promises and challenges that edibles present to both users and policy makers, and the approaches that four states in which recreational cannabis use is legal have taken regarding regulating edibles are described.

Cannabinoids in Medical Practice

  • T. Strouse
  • Medicine
    Cannabis and cannabinoid research
  • 2016
Physicians should be knowledgeable about cannabinoids and should inquire with their patients about cannabinoid use, and Practical suggestions for clinical approaches are included.

Cannabinoids in Medical Practice

Physicians should be knowledgeable about cannabinoids and should inquire with their patients about cannabinoid use, and Practical suggestions for clinical approaches are included.

A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment

Findings support strong correlations among ad libitum THC consumed and THC plasma levels after edible cannabis use and suggest few differences in intoxication and impairment between edible and flower cannabis users after adlibitum use.

Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.

Findings suggest that experienced users who consume a THC+CBD product reported similar levels of positive and psychotomimetic effects relative to those who consumed a THC-only product, despite consuming less THC and displaying lower plasma THC concentrations.

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol

This review aims to provide types of contaminants and examples of Cannabis contamination using case studies that elucidate the medical consequences consumers risk when using adulterated Cannabis products.

Evaluating the Medicinal Uses of Cannabis

A number of elements are responsible for the increased complications of cannabis use, including the increase in the potency of cannabis and an evolution in the ratio between the two primary components, Δ9tetrahydrocannabinol (Δ9-THC) and cannabidiol.

Acute Illness Associated With Cannabis Use, by Route of Exposure

This was a retrospective observational study based on chart review of patients presenting to the UCHealth University of Colorado Hospital Emergency Department (UCHED) to describe and compare adult ED visits associated with edible and inhalable cannabis products.

The Role of Cannabis, Cannabidiol and Other Cannabinoids in Chronic Pain. The Perspective of Physicians.

Surprisingly, systematic studies to date do not support an "entourage effect" of the other plant constituents of cannabis (mainly terpenoids) in treatment of chronic pain, and the only cannabinergic medication available at present is CBD, which is not a "controlled substance".



Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use.

Two cases of "cannabis acute psychosis" following the administration of oral cannabis

While the oral route of administration achieves only limited blood concentrations, significant psychotic reactions may occur, especially in occasional users.

Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects

Particular focus will be placed on phytocannabinoid‐terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin‐resistant Staphylococcus aureus).

Patterns of Medical Marijuana Use Among Individuals Sampled from Medical Marijuana Dispensaries in Los Angeles

Interventions aimed at MM users should stress the related effects of tobacco and risky alcohol use as well as mental health needs.

Sativex® (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data

Sativex oromucosal spray appears to be a useful and welcomed option for the management of resistant spasticity in MS patients, and there are no signs of drug tolerance or withdrawal syndrome, or any evidence of drug misuse or abuse.

The implications of marijuana legalization in Colorado.

The history of marijuana policy in Colorado and the expected and unexpected effects of increased marijuana availability are discussed and other states considering marijuana policy liberalization may learn from the experiences in Colorado.

Measuring Quality of Life in Patients with Schizophrenia

For QOL in schizophrenia to regain its promise, researchers must take the ultimate next step beyond measurement: to develop credible strategies for integrating QOL data in clinical practice.

Prevalence of mental illness among homeless men in the community

This study represents the first attempt within Germany and Europe at a full census of homeless men and concepts aimed at improving the health care system for this target group were found to be dependent in no small measure on the success of the initial contact.